









市場行情
/
股票
/
nasdaq-nams
/

NewAmsterdam Pharma Company NV

NAMS

35.110USD

+1.210+3.57%

收盤 12/19, 16:00（美東）報價延遲15分鐘

3.97B總市值

虧損本益比TTM



NewAmsterdam Pharma Company NV

35.110

+1.210+3.57%

概覽公司財務分析

概覽

公司

財務

分析

關於 NewAmsterdam Pharma Company NV 公司

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

NewAmsterdam Pharma Company NV簡介



公司代碼NAMS

公司名稱NewAmsterdam Pharma Company NV

上市日期Nov 23, 2022

CEODavidson (Michael Harvey)

員工數量68

證券類型Ordinary Share

年結日Nov 23

公司地址Gooimeer 2-35

城市NAARDEN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編1411 DC

電話31352062971

網址https://ir.newamsterdampharma.com/

公司代碼NAMS

上市日期Nov 23, 2022

CEODavidson (Michael Harvey)

NewAmsterdam Pharma Company NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Mark C. Mckenna

Independent Director

6.96K

Mr. Wouter Joustra

Independent Director

Dr. Michael Harvey Davidson, M.D.

Chief Executive Officer, Executive Director

Mr. William H. (Will) Lewis, J.D.

Independent Chairman of the Board

-100.00%

Ms. Louise Kooij

Interim Chief Financial Officer

Ms. Adele M. Gulfo

Independent Director

Dr. Louis Lange, M.D., Ph.D.

Independent Director

Dr. Marc Ditmarsch, M.D.

Chief Development Officer

Dr. James N. Topper, M.D., Ph.D.

Independent Director

Mr. Douglas Kling

Chief Operating Officer

名稱

名稱/職務

職務

持股

持股變動

Mr. Mark C. Mckenna

Independent Director

6.96K

Mr. Wouter Joustra

Independent Director

Dr. Michael Harvey Davidson, M.D.

Chief Executive Officer, Executive Director

Mr. William H. (Will) Lewis, J.D.

Independent Chairman of the Board

-100.00%

Ms. Louise Kooij

Interim Chief Financial Officer

Ms. Adele M. Gulfo

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月19日週三

持股股東

股東類型

持股股東

佔比

Frazier Life Sciences Management, L.P.

14.73%

RA Capital Management, LP

8.94%

Capital World Investors

8.66%

Forbion Capital Partners

8.12%

Viking Global Investors LP

5.71%

其他

53.83%

持股股東

佔比

Frazier Life Sciences Management, L.P.

14.73%

RA Capital Management, LP

8.94%

Capital World Investors

8.66%

Forbion Capital Partners

8.12%

Viking Global Investors LP

5.71%

其他

53.83%

股東類型

持股股東

佔比

Investment Advisor

29.00%

Investment Advisor/Hedge Fund

24.03%

Venture Capital

20.18%

Private Equity

14.73%

Hedge Fund

13.06%

Research Firm

2.38%

Family Office

1.70%

Sovereign Wealth Fund

0.44%

Individual Investor

0.43%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

283

121.74M

107.54%

+4.12M

2025Q2

263

127.89M

114.87%

+4.67M

2025Q1

255

126.71M

112.87%

+7.17M

2024Q4

216

108.34M

98.72%

+13.96M

2024Q3

194

82.73M

88.90%

-12.05M

2024Q2

184

81.92M

90.19%

-12.22M

2024Q1

155

81.92M

90.50%

-4.21M

2023Q4

117

72.34M

86.57%

-9.73M

2023Q3

116

71.44M

85.50%

-13.42M

2023Q2

109

71.10M

86.48%

+7.09M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Frazier Life Sciences Management, L.P.

16.63M

14.76%

+18.71K

+0.11%

Aug 18, 2025

RA Capital Management, LP

10.14M

Jun 30, 2025

Capital World Investors

8.39M

7.45%

+1.59M

+23.37%

Jun 30, 2025

Forbion Capital Partners

9.32M

8.27%

-1.26M

-11.93%

Sep 26, 2025

Viking Global Investors LP

6.98M

6.2%

Jun 30, 2025

Bain Capital Life Sciences Investors, LLC

10.72M

9.52%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.83M

1.62%

+863.17K

+89.58%

Jun 30, 2025

Deerfield Management Company, L.P.

5.12M

4.54%

+1.01M

+24.66%

Jun 30, 2025

Jennison Associates LLC

2.95M

2.62%

-1.02M

-25.79%

Jun 30, 2025

Wellington Management Company, LLP

3.32M

2.95%

-218.98K

-6.18%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Global X Guru Index ETF

1.82%

ALPS Medical Breakthroughs ETF

1.81%

Virtus LifeSci Biotech Clinical Trials ETF

1.22%

First Trust Small Cap Growth AlphaDEX Fund

1.05%

First Trust NASDAQ Pharmaceuticals ETF

0.83%

Capital Group US Small and Mid Cap ETF

0.68%

ProShares Ultra Nasdaq Biotechnology

0.57%

Invesco Dorsey Wright SmallCap Momentum ETF

0.55%

First Trust Small Cap Core Alphadex Fund

0.43%

Invesco Nasdaq Biotechnology ETF

0.42%

Global X Guru Index ETF

佔比1.82%

ALPS Medical Breakthroughs ETF

佔比1.81%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.22%

First Trust Small Cap Growth AlphaDEX Fund

佔比1.05%

First Trust NASDAQ Pharmaceuticals ETF

佔比0.83%

Capital Group US Small and Mid Cap ETF

佔比0.68%

ProShares Ultra Nasdaq Biotechnology

佔比0.57%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.55%

First Trust Small Cap Core Alphadex Fund

佔比0.43%

Invesco Nasdaq Biotechnology ETF

佔比0.42%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

NewAmsterdam Pharma Company NV的前五大股東是誰？



NewAmsterdam Pharma Company NV的前五大股東如下：
Frazier Life Sciences Management, L.P.
持有股份：16.63M
佔總股份比例：14.76%。
RA Capital Management, LP
持有股份：10.14M
佔總股份比例：9.00%。
Capital World Investors
持有股份：8.39M
佔總股份比例：7.45%。
Forbion Capital Partners
持有股份：9.32M
佔總股份比例：8.27%。
Viking Global Investors LP
持有股份：6.98M
佔總股份比例：6.20%。